Platelet volume could predict the efficacy of thrombopoietin receptor agonists in the treatment of patients with primary immune thrombocytopenia

Documenti analoghi

• Changes in plasma lipid composition upon glucocorticoid treatment in patients with primary immune thrombocytopenia
  di: Lili Ji, et al.
  Pubblicazione: (2025)
• Patients with symptoms of haemolytic anaemia and thrombocytopenia revealed by genetic testing as sitosterolemia
  di: Mengjia Qian, et al.
  Pubblicazione: (2025)
• Hetrombopag: A promising thrombopoietin receptor agonist for the treatment of primary and secondary immune thrombocytopenia
  di: Jiaqi Hu, et al.
  Pubblicazione: (2025)
• Anti‐PF4 antibody inhibit proliferation of lung cancer cells without TP53 mutation by inducing apoptosis and cell cycle arrest
  di: Mengjia Qian, et al.
  Pubblicazione: (2025)
• Titin gene mutations enhance radiotherapy efficacy via modulation of tumour immune microenvironment in rectum adenocarcinoma
  di: Hengchang Liu, et al.
  Pubblicazione: (2025)